1.  Chemistry 210  By Eugene Z urlich. UWIRIN GIYIMINA.

2.  This research is aimed to show that bexarotene can be combined with Taxol with prevent Taxol resistance.  The study was conducted in human breast cancer and ten rodent breast cancer.

3.  Human Breast cancer cell were planted in cell culture medium to Targretin with Taxol.  After three days, Targretin did not prevent Taxol anti-cancer activity.  After multiple exposure, Targretin and Taxol inhibit tumor cell growth completely.  However, with Taxol alone the cancerous cells developed resistance to Taxol, and cross- resistance to the other cancer drugs vincristine, vinblastine and doxorubicin. vincristinevinblastinedoxorubicin

4.  Also treating, cancerous cells with Taxol resistance with Targretin,Taxol,doroxubicin alone no change.  With Targretin and Taxol, The resistant cancer cells die.

5.  The treatment in rodents breast cancer cell, the result was like this after six weeks:  mice treated with the Targretin / Taxol combination had a mean 77% decrease in their overall tumor burden In contrast, mice treated with Taxol alone had a 42% increase in tumor burden, those treated with Targretin alone had an 84% increase, and those in the control group had a 474% increase.  This shows that Targretin with Taxol is a better chemotherapy drug for Taxol resistance

6.  As it was shown from both in vivo and in vitro, the paclitaxel can be used to treat human breast cancer cell with Taxol resistance

7.  The paclitaxel has side effects such as: pale skin, easy bruising or unusual weakness; fever, chills, body aches, flu symptoms; white patches or sores inside your mouth

8.  The side effects due to Paclitaxel can be reduced by Taxotere; it has a tert- butoxycarbonyl group instead of the benzoyl group on the Taxol side chain and a hydroxyl group instead of the acetoyl group on the Taxol B ring.  Consult your physician if you have one of those effects immediately.

9.  This research was done by Holsinger et.al and there still researching about Taxol.  In March of 2001, Ligand announced results of a Phase II study of Targretin for the treatment

10.  In future, the research will continue on Taxol resistance that is caused by efflux pump embedded in P-glycoprotein.

11. http://www.thefreelibrary.com/Ligand's+Targr etin+Combined+With+Taxol+Prevents+and+O vercomes...-a099782957